Rachel Leibman

Rachel Leibman is a Scientific Director in Oncology Clinical Development at AbbVie, a global pharmaceutical company.1 She is based in San Francisco, California, and specializes in early-phase immuno-oncology clinical development.2

Professional Background

Rachel has a strong background in clinical protocol writing and oncology research. Prior to her current role, she worked at Stemcentrx, an oncology biotech startup that was later acquired by AbbVie.3 Her career progression at AbbVie includes:

• Starting as an Associate Scientific Director in early-phase immuno-oncology clinical development
• Advancing to her current position as Scientific Director (Oncology Clinical Development), which she began in August 20234

Education and Expertise

Rachel Leibman holds a degree from the University of Pennsylvania.1 Her expertise includes:

• Oncology clinical development
• Immuno-oncology research
• Clinical protocol writing
• Early-phase clinical trials

Research Contributions

Rachel has made contributions to the field of oncology research. She has authored or co-authored at least 4 research works, which have received 8 citations.5 One of her notable research contributions includes a first-in-human study of ABBV-514 as monotherapy and in combination with budigalimab.5

Rachel Leibman's LinkedIn profile can be found under the username rachel-leibman-1156a88a, where more details about her professional experience and accomplishments may be available.1